Ifebemtinib plus garsorasib as first-line treatment for KRAS G12C -mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.
Lancet Respir MedJul 7, 2026 (epub)
Zhengbo Song, Xingya Li, Rongbo Lin et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicentre, single-arm phase 2 trial evaluated the efficacy and safety of ifebemtinib plus garsorasib in 33 treatment-naive patients with KRAS G12C-mutated non-small-cell lung cancer (NSCLC) in China. The study found a confirmed objective response rate (ORR) of 82% (27 of 33 patients), indicating promising efficacy for this dual-oral regimen.
Key findings
- Confirmed objective response rate (ORR) was 82% (27 of 33 patients; 95% CI 64.5-93.0).
- All 33 patients reported treatment-emergent adverse events, with 33% experiencing grade 3 or 4 events.
- Serious adverse events occurred in 27% of patients, with intracranial hemorrhage and pneumonia reported in at least two patients.
Why it matters
The findings suggest that ifebemtinib plus garsorasib may offer an effective treatment option for patients with KRAS G12C-mutated NSCLC, a population with limited therapeutic options. Understanding the safety profile is crucial for clinical decision-making.